Centessa Pharmaceuticals (CNTA) Accumulated Expenses (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Accumulated Expenses data on file, last reported at $25.9 million in Q1 2026.

• Quarterly Accumulated Expenses rose 35.9% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (up 35.9% YoY) and the FY2025 annual result came in at $35.4 million, down 30.48% from the prior year.
• Accumulated Expenses fell to $25.9 million in Q1 2026 per CNTA's latest filing, from $35.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $50.9 million in Q4 2024 and bottomed at $15.3 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $24.0 million (2025), against an average of $24.9 million.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 155.74%; it then slumped 30.48% in 2025.
• Tracing CNTA's Accumulated Expenses over 5 years: stood at $24.5 million in 2022, then rose by 12.52% to $27.6 million in 2023, then soared by 84.46% to $50.9 million in 2024, then tumbled by 30.48% to $35.4 million in 2025, then fell by 26.69% to $25.9 million in 2026.
• Per Business Quant, the three latest CNTA Accumulated Expenses figures stand at $25.9 million (Q1 2026), $35.4 million (Q4 2025), and $20.4 million (Q3 2025).

Peer Comparison